Search Within

Kathryn Cecilia Arbour

Formats
  1. Meeting Abstract (43)
  2. Journal Article (42)
  3. Editorial (2)
  4. Review (2)
Groups
  1. Department of Medicine (89)
  2. Solid Tumor Oncology Division (89)
  3. Thoracic Oncology (89)
  4. Weinberg Fellows (89)
  5. GSK Faculty (39)
  6. Radiology, Department of (34)

More Groups

People
  1. Gregory Riely (42)
  2. Matthew Hellmann (40)
  3. Hira Rizvi (32)
  4. Andrew Plodkowski (23)
  5. Charles Rudin (22)
  6. Mark Kris (22)

More People

Years
  1. 2025 (5)
  2. 2024 (10)
  3. 2023 (8)
  4. 2022 (9)
  5. 2021 (11)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Annals of Oncology (11)
  3. Journal of Thoracic Oncology (11)
  4. Clinical Cancer Research (6)
  5. Cancer Research (4)
  6. Cancer Discovery (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (32)
  2. Elsevier Inc. (16)
  3. American Association for Cancer Research (13)
  4. Oxford University Press (13)
  5. Nature Publishing Group (4)
  6. Massachusetts Medical Society (2)

More Publishers

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC
    Meeting Abstract

    Thummalapalli, R.; Muldoon, D.; Febres-Aldana, C. A.; Falcon, C. J.; Pupo, A.; Bandlamudi, C.; Berger, M. F.; Yu, H. A.; Riely, G. J.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Nishio, M.; Negrao, M. V.; Arbour, K. C.; Burns, T. F.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Hochmair, M.; Leal, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
    Journal Article

    Jiang, J.; Jiang, L.; Maldonato, B. J.; Wang, Y.; Holderfield, M.; Aronchik, I.; Winters, I. P.; Salman, Z.; Blaj, C.; Menard, M.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: A phase 1b trial
    Journal Article

    Desai, J.; Alonso, G.; Kim, S. H.; Cervantes, A.; Karasic, T.; Medina, L.; Shacham-Shmueli, E.; Cosman, R.; Falcon, A.; Gort, E.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer
    Journal Article

    Thummalapalli, R.; Bernstein, E.; Herzberg, B.; Li, B. T.; Iqbal, A.; Preeshagul, I.; Santini, F. C.; Eng, J.; Ladanyi, M.; Yang, S. R.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • The impact of co-alterations on outcomes after local therapy for patients with KRAS-mutant lung adenocarcinoma brain metastases
    Meeting Abstract

    Eichholz, J.; Gaeta, B.; Walch, H.; Boe, L.; Kratochvil, L.; del Balzo, L. A.; Yamada, Y.; Yu, Y.; Zinovoy, M.; Gomez, D. R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Arbour, K. C.; Punekar, S.; Garrido-Laguna, I.; Hong, D. S.; Wolpin, B.; Pelster, M. S.; Barve, M.; Starodub, A.; Sommerhalder, D.; Chang, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer
    Journal Article

    Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer
    Journal Article

    Engstrom, L. D.; Aranda, R.; Waters, L.; Moya, K.; Bowcut, V.; Vegar, L.; Trinh, D.; Hebbert, A.; Smith, C. R.; Kulyk, S.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save